Nurix Therapeutics financials
$23.68+0.02%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Nov 30 | FY24 Nov 30 | FY23 Nov 30 | FY22 Nov 30 | FY21 Nov 30 | FY20 Nov 30 |
|---|---|---|---|---|---|---|
| Revenue | $84.0M | $54.5M | $77.0M | $38.6M | $29.8M | $17.8M |
| Gross profit | $84.0M | $54.5M | $77.0M | $38.6M | $29.8M | $17.8M |
| Gross margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating income | -$285.7M | -$213.0M | -$155.1M | -$183.9M | -$117.9M | -$65.0M |
| Net income | -$264.5M | -$193.6M | -$143.9M | -$180.4M | -$117.2M | -$43.2M |
| Net margin | −314.9% | −354.9% | −187.0% | −466.9% | −393.9% | −242.7% |
| Diluted EPS | $-3.05 | $-2.88 | $-2.65 | $-3.71 | $-2.73 | $-2.76 |
| EBITDA | -$276.9M | -$203.7M | -$147.5M | -$178.5M | -$111.8M | -$62.8M |
| Operating cash flow | -$249.5M | -$172.6M | -$81.4M | -$159.8M | -$84.4M | -$80.0K |
| Free cash flow | -$263.5M | -$181.9M | -$89.8M | -$172.1M | -$90.0M | -$4.6M |
| Diluted shares | 86.7M | 67.1M | 54.3M | 48.6M | 42.9M | 15.7M |
Balance sheet
| Period end | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 | Nov 30 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $247.0M | $110.0M | $54.6M | $64.5M | $80.5M | $119.4M |
| Short-term investments | $346.0M | $499.6M | $233.3M | $244.7M | $215.2M | $161.8M |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $688.1M | $669.3M | $355.6M | $416.8M | $476.8M | $396.3M |
| Total liabilities | $149.4M | $142.3M | $155.1M | $113.1M | $134.5M | $106.1M |
| Shareholders' equity | $538.7M | $527.0M | $200.5M | $303.7M | $342.3M | $290.3M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology